Novo Nordisk NVO announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body weight and ...

Anita Courcoulas, MD, defines GLP-1s as “generation one;” dual GLP-1 and GIPs as the second; and a triple threat of GLP-1, GIP and GCGRs as the third generation of weight loss drugs. Dr. Courcoulas is ...

A behind-the-scenes blog about research methods at Pew Research Center. For our latest findings, visit pewresearch.org. (Related posts: 5 things to keep in mind when you hear about Gen Z, Millennials, ...

Ask any sales leader why their company loses deals, and they’ll confidently tell you: "We talk to our customers every day. We know why we win and why we lose." Most companies, though, think they are ...